ABUS
Price
$3.88Alerts
Change
+$0.06 (+1.57%)
Updated
Nov 11 closing price
Capitalization
724.08M
One day until earnings call
Intraday BUY SELL Signals
CVKD
Price
$1.45Alerts
Change
+$0.01 (+0.69%)
Updated
Nov 11 closing price
Capitalization
3.5M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs CVKD

ABUS vs CVKD Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABUS vs. CVKD commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and CVKD is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABUS with price predictions
Nov 10, 2026

ABUS's Indicator enters downward trend

The Aroon Indicator for ABUS entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 180 cases the stock moved lower. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In 63 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.799) is normal, around the industry mean (3.498). P/E Ratio (4.627) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for CVKD with price predictions
Nov 10, 2026

Aroon Indicator for CVKD shows an upward move is likely

CVKD's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 113 similar instances where the Aroon Indicator showed a similar pattern. In 99 of the 113 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CVKD as a result. In 46 of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

CVKD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CVKD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +46.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 146 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

CVKD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.854) is normal, around the industry mean (3.498). P/E Ratio (-0.201) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CVKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABUS: Fundamental Ratings
ABUS
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
59
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABUSCVKD
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ABUS: $3.82 vs. CVKD: $1.44)
Brand notoriety: ABUS and CVKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 47% vs. CVKD: 158%
Market capitalization -- ABUS: $724.08M vs. CVKD: $3.5M
ABUS [@Biotechnology] is valued at $724.08M. CVKD’s [@Biotechnology] market capitalization is $3.5M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 1 FA rating(s) are green while CVKD’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 1 green, 4 red.
  • CVKD’s FA Score: 1 green, 4 red.
According to our system of comparison, CVKD is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while CVKD’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • CVKD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CVKD is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -1.55% price change this week, while CVKD (@Biotechnology) price change was +27.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CVKD and

Correlation & Price change

A.I.dvisor tells us that CVKD and RADX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVKD and RADX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVKD
1D Price
Change %
CVKD100%
+5.11%
RADX - CVKD
31%
Poorly correlated
-3.95%
VIR - CVKD
29%
Poorly correlated
-3.63%
GDTC - CVKD
29%
Poorly correlated
+0.12%
OKUR - CVKD
28%
Poorly correlated
+6.11%
ABUS - CVKD
26%
Poorly correlated
+2.69%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOC20.41-0.21
-1.02%
Healthpeak Properties
WLYB50.25-1.80
-3.46%
John Wiley & Sons
GRWG1.51-0.06
-3.82%
GrowGeneration Corp
ICCM0.78-0.04
-5.03%
Icecure Medical Ltd
CAPR8.87-0.98
-9.95%
Capricor Therapeutics